CClinicalTrials.gg
CompletedNCT02365857Updated Feb 2, 2016

Intrathecal Dexmedetomidine With Bupivacaine for Spinal Anesthesia in Cesarean Section

A Phase 4 interventional study of Dexmedetomidine & Bupivacaine. and Bupivacaine Only. in Anesthesia, Spinal, sponsored by Cairo University. Completed. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-02.

Sponsored by Cairo University · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

A Randomized, Controlled, Double blind study aiming to evaluate the analgesic potentials and side effect profile of different dose levels of Dexmedetomidine added to subarachnoid bupivacaine in full-term pregnant women undergoing elective cesarean section using spinal anesthesia. The investigators ultimate goal is to find out the least effective dose which will be associated with minimal or no side effects. The primary outcome will be the time to two sensory block segment regression.

Read the detailed description

Alpha 2-agonists are non-opioid adjuvants with a significant role in extending the analgesic duration of subarachnoid block. When clonidine or Dexmedetomidine was added to intrathecal local anesthetics, the regression of sensory and motor blocks increased dose-dependently. Further, a recent meta-analysis including seven randomized controlled studies reported an increase in the duration of analgesia and reduced morphine requirement after the concomitant subarachnoid administration of clonidine.

Animal studies demonstrated that Dexmedetomidine added to bupivacaine significantly enhanced the duration of sensory and motor blockade of sciatic nerve block. Histo-pathological examination proved that all of the nerves analyzed had normal axons and myelin at 24 h and 14 days after the peri-neural administration of Dexmedetomidine. Several clinical studies confirmed the analgesic potentials and safe neurological outcome of neuraxially administered Dexmedetomidine in the non-obstetric settings while intrathecal clonidine proved to be a useful analgesic adjunct for spinal anesthesia in patients undergoing cesarean section. But to the best of the investigator knowledge the effects of intrathecal Dexmedetomidine on the perioperative clinical profile of bupivacaine-induced spinal anesthesia were not studied before in the obstetric patient population.

02

Conditions studied

  • Anesthesia, Spinal

Keywords

  • spinal anesthesia
  • caesarian section
  • Dexmedetomidine
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Full-term pregnant women.
  • Elective cesarean section using spinal anesthesia.
  • Singleton gestation.
  • American Society of Anesthesiologists (ASA) physical status classes I and II.

Exclusion criteria

Exclusion Criteria:

  • Preterm pregnancy (\<37 wks gestation).
  • Multiple gestation.
  • Cardiovascular disease (e.g., preeclampsia, hypertension) and the use of antihypertensive medication.
  • Conditions that preclude spinal anesthesia.
  • Failed spinal block and conversion to general anesthesia.
  • A history of established chronic pain.
  • Drug addiction.
  • A psychiatric disorder.
  • Inability to communicate effectively.
  • Asthma and allergy to non-steroidal anti-inflammatory drugs.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    DEX-5

    Dexmedetomidine \& Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.

    Drug: Dexmedetomidine & Bupivacaine.

  • Active comparator
    DEX-10

    Dexmedetomidine \& Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.

    Drug: Dexmedetomidine & Bupivacaine.

  • Active comparator
    DEX-15

    Dexmedetomidine \& Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.

    Drug: Dexmedetomidine & Bupivacaine.

  • Active comparator
    Control

    Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.

    Drug: Bupivacaine Only.

Interventions

  • DrugDexmedetomidine & Bupivacaine.

    Intrathecal injection of Dexmedetomidine \& Bupivacaine.

  • DrugBupivacaine Only.

    Intrathecal injection of Bupivacaine only.

06

What researchers measure

Primary outcomes

  1. The time to two sensory block segment regression.

    Define the start of regression of the level of sensory block

    Time frame: 70 min

Secondary outcomes

  1. The peak sensory level of the block.

    By Pin Prick testing.

    Time frame: 10 min

  2. Time from intrathecal injection to peak sensory block level.

    Define the speed of onset of the block.

    Time frame: 10 min

  3. Time to S1 level sensory regression.

    Define duration of the block.

    Time frame: 70 min

  4. Degree of motor block.

    By Modified Bromage Score.

    Time frame: 24 h

  5. Intraoperative hemodynamic variables.

    Detect frequency of side effects

    Time frame: 24 h

  6. The total dose of ephedrine/atropine required to maintain hemodynamic stability.

    Detect frequency of side effects

    Time frame: 24 h

  7. The amount of lactated Ringer's solution required intraoperatively to maintain normal Blood pressure range

    Detect frequency of side effects

    Time frame: 24 h

  8. Oxygen saturation (the need for O2 supplementation)

    Detect frequency of side effects

    Time frame: 24 h

  9. Intraoperative analgesic supplementation

    Define quality of the block

    Time frame: 70 min

  10. Time to first postoperative rescue analgesic request

    Define duration of analgesia by the block

    Time frame: 24 h

  11. Postoperative pain scores for 24 hours

    Define duration of analgesia by the block

    Time frame: 24 h

  12. Frequency of administration of postoperative analgesics

    Define duration of analgesia by the block

    Time frame: 24 h

  13. Intraoperative sedation scores

    Detect frequency of side effects

    Time frame: 24 h

  14. Incidence of side effects (nausea, vomiting, shivering, pruritus, respiratory depression, and desaturation)

    Detect frequency of side effects

    Time frame: 24 h

  15. New born Apgar Score

    Detect any effects on the new born at different dose levels

    Time frame: 5 min

  16. Duration of motor block.

    By Modified Bromage Score.

    Time frame: 24 h

  17. Early postoperative hemodynamic variables.

    Detect frequency of side effects

    Time frame: 24 h

  18. Total dose of postoperative analgesics

    Define duration of analgesia by the block

    Time frame: 24 h

  19. Postoperative sedation scores

    Detect frequency of side effects

    Time frame: 24 h

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02365857
Lead sponsor
Cairo University
Responsible party
Professor Mohamed Abdulatif Mohamed (Abdulatif M., Cairo University) — Principal investigator
First posted
Feb 19, 2015
Start date
Dec 2014
Primary completion
Jul 2015
Completion
Oct 2015
Last update
Feb 2, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion